Biomerica signs CDMO services deal for over $1.75 million in IVD assay development fees
Biomerica, Inc.
Silvercorp Metals Inc.
Rentokil Initial plc Sponsored ADR
Biomerica, Inc. BMRA | 0.00 | |
Silvercorp Metals Inc. SVM | 0.00 | |
Rentokil Initial plc Sponsored ADR RTO | 0.00 |
- Biomerica signed a Master Services Agreement with a confidential life sciences company to develop proprietary IVD assays.
- Initial contract development target fee exceeds USD 1.75 million, earned across multiple statements of work under the agreement.
- Three-year term with automatic one-year renewals; revenue recognized on milestone completion as deliverables are accepted.
- Work to be performed at its FDA-licensed, ISO 13485-certified Irvine facility using existing staff and equipment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomerica Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605280819PRIMZONEFULLFEED9727956) on May 28, 2026, and is solely responsible for the information contained therein.
